Ocular Therapeutix (OCUL) Aandelenoverzicht
Ocular Therapeutix, Inc. is een biofarmaceutisch bedrijf dat zich bezighoudt met de ontwikkeling en commercialisering van therapieën voor netvliesaandoeningen en andere oogaandoeningen met behulp van zijn op bioresorbeerbare hydrogel gebaseerde formuleringstechnologie in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
OCUL Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
LO
Lou_Basenese
Community ContributorUS$7.6FV • 76.8% ondergewaardeerd intrinsieke korting
5022.2%Revenue growth p.a.
3.7k
22
2
54
Ocular Therapeutix, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$9.21 |
| 52 Week Hoogtepunt | US$16.44 |
| 52 Week Laag | US$6.23 |
| Bèta | 0.95 |
| 1 maand verandering | 8.74% |
| 3 maanden verandering | 0.77% |
| 1 Jaar Verandering | 7.97% |
| 3 jaar verandering | 51.23% |
| 5 jaar verandering | -41.97% |
| Verandering sinds IPO | -29.96% |
Recent nieuws en updates
OCUL: SOL-1 Data Clarity Will Support Future Retinal Franchise Upside
Analysts have lifted their blended 12 month price target on Ocular Therapeutix by about $1 to $27, citing detailed SOL-1 Phase 3 data that in their view clarify approval odds, support Axpaxli's potential in wet age related macular degeneration and diabetic retinopathy, and help offset recent share price volatility. Analyst Commentary Recent research updates focus heavily on how the detailed SOL-1 Phase 3 data could influence Axpaxli's clinical positioning, regulatory outlook, and Ocular Therapeutix's valuation, especially after a sharp share price pullback.
OCUL: SOL-1 Phase 3 Data Will Drive Bullish Repricing
Ocular Therapeutix's updated analyst price targets, which now range from $27 to $34, reflect analysts' view that detailed Phase 3 SOL-1 data for Axpaxli clarify key efficacy and safety questions and support the case for potential approval in wet AMD and diabetic retinopathy. Analyst Commentary Recent research following the full Phase 3 SOL-1 readout has been broadly constructive, with several firms lifting price targets into the US$27 to US$34 range.OCUL: Phase 3 SOL-1 Clarity Will Drive Future Retinal Upside
Analysts have lifted their average price target for Ocular Therapeutix by about $2, citing detailed Phase 3 SOL-1 data that they say clarify the approval path for Axpaxli and reduce perceived risk in the broader retinal program. Analyst Commentary Recent research updates show a wide range of views on how Axpaxli and the SOL-1 data could influence Ocular Therapeutix's valuation and execution risk.
OCUL: Phase 3 Retinal Data And Potential Sanofi Bid Will Reshape Outlook
Analysts have raised the implied fair value estimate for Ocular Therapeutix to $34 from $31, citing refreshed price targets in the $27 to $34 range and detailed SOL-1 trial data. They say these data clarify approval prospects and support Axpaxli's potential role in large eye disease markets.Recent updates
OCUL: SOL-1 Data Clarity Will Support Future Retinal Franchise Upside
Analysts have lifted their blended 12 month price target on Ocular Therapeutix by about $1 to $27, citing detailed SOL-1 Phase 3 data that in their view clarify approval odds, support Axpaxli's potential in wet age related macular degeneration and diabetic retinopathy, and help offset recent share price volatility. Analyst Commentary Recent research updates focus heavily on how the detailed SOL-1 Phase 3 data could influence Axpaxli's clinical positioning, regulatory outlook, and Ocular Therapeutix's valuation, especially after a sharp share price pullback.OCUL: SOL-1 Phase 3 Data Will Drive Bullish Repricing
Ocular Therapeutix's updated analyst price targets, which now range from $27 to $34, reflect analysts' view that detailed Phase 3 SOL-1 data for Axpaxli clarify key efficacy and safety questions and support the case for potential approval in wet AMD and diabetic retinopathy. Analyst Commentary Recent research following the full Phase 3 SOL-1 readout has been broadly constructive, with several firms lifting price targets into the US$27 to US$34 range.OCUL: Phase 3 SOL-1 Clarity Will Drive Future Retinal Upside
Analysts have lifted their average price target for Ocular Therapeutix by about $2, citing detailed Phase 3 SOL-1 data that they say clarify the approval path for Axpaxli and reduce perceived risk in the broader retinal program. Analyst Commentary Recent research updates show a wide range of views on how Axpaxli and the SOL-1 data could influence Ocular Therapeutix's valuation and execution risk.OCUL: Phase 3 Retinal Data And Potential Sanofi Bid Will Reshape Outlook
Analysts have raised the implied fair value estimate for Ocular Therapeutix to $34 from $31, citing refreshed price targets in the $27 to $34 range and detailed SOL-1 trial data. They say these data clarify approval prospects and support Axpaxli's potential role in large eye disease markets.OCUL: Higher Sanofi Bid And SOL-1 Data Will Drive Bullish Repricing
The analyst price target for Ocular Therapeutix has been adjusted from $20 to $18 as analysts factor in updated fair value estimates, along with views that Axpaxli data from the SOL-1 trial supports potential durability and safety in the large wet AMD market. Analyst Commentary Recent Street research reflects a mixed but generally supportive stance toward Ocular Therapeutix following the SOL-1 trial readout.Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing
Feb 17OCUL: Potential Higher Sanofi Bid Will Drive Bullish Repricing
Analysts have adjusted their price target on Ocular Therapeutix to $20.00 from $19.00, reflecting updated assumptions around revenue growth, profit margins, discount rate and future P/E that they view as more closely aligned with the company’s current outlook. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, signaling continuing interest in the company as a potential acquisition target (IBD, Periodicals).OCUL: Potential Sanofi Bid And Phase 3 Milestones Will Drive Repricing
Analysts have raised their fair value estimate for Ocular Therapeutix from US$14.00 to US$19.00, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers of the new price target. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, according to Investor's Business Daily, highlighting ongoing interest from a large pharmaceutical partner (IBD).OCUL: Potential Sanofi Bid And Late Stage Trials Will Reshape Outlook
Analysts now put their fair value estimate for Ocular Therapeutix at US$31.00, up from US$22.00. They cite revised assumptions for revenue growth, profit margins and future P/E that change their overall risk and return outlook for the stock.Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Stock Retreats 29% But Revenues Haven't Escaped The Attention Of Investors
Jan 08
OCUL: Phase 3 Retinal Program Progress Will Drive Future Upside Potential
Analysts have reaffirmed their price target on Ocular Therapeutix at roughly US$24.17 per share, citing largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E that together support a stable fair value outlook. What's in the News Ocular Therapeutix plans to enter a quiet period starting 20 December 2025 as it prepares for database lock for the SOL-1 Phase 3 trial of AXPAXLI for wet age-related macular degeneration.OCUL: Derisked Diabetic Retinopathy Pivotal Program Will Drive Future Upside Potential
Analysts raised their price target on Ocular Therapeutix by approximately $1.25 per share, citing derisking of the pivotal Nonproliferative Diabetic Retinopathy program and the potential for blockbuster revenue growth, along with upcoming wet AMD pivotal readouts that are expected to drive meaningful near term value creation. Analyst Commentary Bullish analysts view the updated price target as a reflection of increased confidence in Ocular Therapeutix's execution against its late stage ophthalmology pipeline, particularly in Nonproliferative Diabetic Retinopathy and wet AMD.OCUL: Pivotal Retinopathy Trial Progress Will Drive Substantial Upside Potential
Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing new developments in a derisked pivotal program for Nonproliferative Diabetic Retinopathy as well as potential near-term value from upcoming wet AMD trial readouts. Analyst Commentary Following the recent price target increase for Ocular Therapeutix, analysts have provided a range of perspectives on the company's opportunities and risks.OCUL: Pivotal Trial Progress in Diabetic Retinopathy Will Drive Long-Term Upside
Analysts have increased their price target for Ocular Therapeutix by $1.00 to $22.92, citing recently derisked pivotal programs that enhance the company's potential for both near-term and long-term value creation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the recent price target increase as evidence of growing confidence in the company's clinical programs and strategic direction.OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
Analysts have increased their price target for Ocular Therapeutix from $20 to $29, citing the newly derisked pivotal program in Nonproliferative Diabetic Retinopathy and anticipated value from upcoming wet AMD trial results as justification for their greater optimism. Analyst Commentary Recent analyst discussions have centered on the positive momentum surrounding Ocular Therapeutix due to its progress in developing treatments for retinal diseases.Future Drug Approvals Will Expand Retinal Disease Treatments
Ocular Therapeutix saw its analyst price target increase significantly from $20 to $29, as analysts cite newly available de-risked data in Nonproliferative Diabetic Retinopathy and upcoming pivotal readouts in wet AMD as key drivers of enhanced valuation. Analyst Commentary Following the recent price target revision, analysts have weighed in with both optimistic and cautious perspectives regarding Ocular Therapeutix's outlook.Future Drug Approvals Will Expand Retinal Disease Treatments
Analysts have raised their fair value estimate for Ocular Therapeutix from $17.45 to $20.17 per share, citing increased clarity around the company's pivotal program in Nonproliferative Diabetic Retinopathy and its emerging opportunities in wet AMD. Analyst Commentary Analysts have provided detailed insights following recent developments at Ocular Therapeutix, offering a balanced perspective on both the opportunities and challenges influencing the company's valuation and future growth prospects.After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar
Jul 29Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors
Jun 10Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry?
May 29Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates
May 07Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S
Mar 25
FDA Approval And Adjusted Trials Will Expand Treatment Options
AXPAXLI's FDA amendment enables better dosing schedules, boosting market penetration and revenue through superior treatment durability.Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Mar 06Does Ocular Therapeutix (NASDAQ:OCUL) Have A Healthy Balance Sheet?
Feb 25Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Rendement voor aandeelhouders
| OCUL | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -4.0% | -3.2% | -0.2% |
| 1Y | 8.0% | 16.0% | 27.6% |
Rendement versus industrie: OCUL presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 16 % opleverde.
Rendement versus markt: OCUL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 27.6 % opleverde.
Prijsvolatiliteit
| OCUL volatility | |
|---|---|
| OCUL Average Weekly Movement | 13.4% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabiele aandelenkoers: De aandelenkoers van OCUL is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van OCUL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2006 | 325 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling en commercialisering van therapieën voor netvliesaandoeningen en andere oogaandoeningen met behulp van zijn op bioresorbeerbare hydrogel gebaseerde formuleringstechnologie in de Verenigde Staten. Het bedrijf brengt DEXTENZA op de markt, een dexamethason oogheelkundige inbrenghuls voor de behandeling van oogontsteking en pijn na oogheelkundige chirurgie, evenals allergische conjunctivitis. Het ontwikkelt ook AXPAXLI, een axitinib intravitreale hydrogel die zich in fase 3 van klinische studies bevindt voor de behandeling van natte leeftijdsgebonden maculaire degeneratie en niet-proliferatieve diabetische retinopathie; OTX-TIC, een travoprost intracamerale hydrogel, die fase 2 van klinische studies heeft voltooid voor de behandeling van open-hoek glaucoom of oculaire hypertensie.
Ocular Therapeutix, Inc. Samenvatting
| OCUL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.00b |
| Inkomsten(TTM) | -US$265.94m |
| Inkomsten(TTM) | US$51.95m |
38.6x
P/S-verhouding-7.5x
Koers/WinstverhoudingIs OCUL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| OCUL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$51.95m |
| Kosten van inkomsten | US$203.67m |
| Brutowinst | -US$151.72m |
| Overige uitgaven | US$114.22m |
| Inkomsten | -US$265.94m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
May 05, 2026
| Winst per aandeel (EPS) | -1.22 |
| Brutomarge | -292.04% |
| Nettowinstmarge | -511.90% |
| Schuld/Eigen Vermogen Verhouding | 10.9% |
Hoe presteerde OCUL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/30 12:25 |
| Aandelenkoers aan het einde van de dag | 2026/04/29 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ocular Therapeutix, Inc. wordt gevolgd door 25 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Colleen Kusy | Baird |
| Anita Dushyanth | Berenberg |
| Tazeen Ahmad | BofA Global Research |